---
rank: 1
isComplete: true
---

<span class="investment__name">Corvita Corporation</span> developed two new biomaterials and designed endovascular grafts for treatment of thoracic and abdominal aortic aneurysms. Corvita scientists also developed and licensed to Cordis the materials system used to produce most of the angioplasty balloon products now in use throughout the world. The company completed an IPO in November 1994 and was sold to Pfizer in May of 1996. Subsequently, Pfizer sold the business to Boston Scientific. BSX uses a Corvita developed biomaterial as the polymer carrier on all of their drug coated stents. Partisan had a 22 times cash-on-cash return on Corvita.